BRKR
Medical Devices · Healthcare
CEO
Equibles does not estimate personal net worth.
Get an email with a short summary when Bruker Corp publishes a filing, an earnings call transcript or a press release.
Get BRKR alertsFrank Laukien is recorded as CEO at Bruker Corp (BRKR). The newest filing on record that lists Frank Laukien as CEO at Bruker Corp (BRKR) is dated April 10, 2026. The proxy statement of Bruker Corp reports total compensation of $4,706,388 for Frank Laukien in fiscal 2025, including a base salary of $976,554. Disclosed compensation is on record for 9 fiscal years. Frank Laukien has spoken on 25 earnings calls across 1 company, most recently for Bruker Corp on August 4, 2026. Bruker Corp is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Bruker Corp includes Burkhard A. Prause (CEO), Gerald Herman (CFO), Thomas Bures (Chief Accounting Officer) and 7 others.
“Good morning, everyone, and thank you for joining us on today's second quarter 2026 earnings call. We are pleased that Bruker has returned to organic revenue growth in the second quarter and that our focus on cost reduction and profitability improvements resulted in solid margin expansion and non-GAAP EPS growth.”
“Good morning, everyone, and thank you for joining us on today's fourth quarter 25 earnings call. At the conclusion of a difficult year, 2025, with headwinds from academic funding, tariffs and currencies, we are pleased that in the fourth quarter we delivered revenues ahead of our expectations.”
“Good morning, everyone, and thank you for joining us on today's third quarter 2025 earnings call. As forecasted, our third quarter revenues and earnings were down year over year, primarily due to weaker academic and research instruments demand in the first half of 2025.”
“Good morning, everyone, and thank you for joining us on today's second quarter 2025 earnings call. Life science research instruments markets are under pressure at the moment, with expected U.S. academic funding headwinds and China stimulus delays for high-end research instrumentation.”
“Good morning, everyone, and thank you for joining us on today's first quarter 2025 earnings call. Bruker had a solid start to 2025 with double-digit reported and constant exchange rate or CER revenue growth.”
Start not stated–present
Last confirmed April 10, 2026
BRKR
Medical Devices · Healthcare
CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Bruker Corp (BRKR) | Chairman, President and Chief Executive Officer | $976,554 | $4,706,388 |
| 2024 | Bruker Corp (BRKR) | Chairman, President and Chief Executive Officer | $965,720 | $5,527,304 |
| 2023 | Bruker Corp (BRKR) | Chairman, President and Chief Executive Officer | $926,096 | $5,858,761 |
| 2022 | Bruker Corp (BRKR) | Chairman, President and Chief Executive Officer | $873,265 | $5,057,195 |
| 2021 | Bruker Corp (BRKR) | Chairman, President and Chief Executive Officer | $811,581 | $5,594,539 |
| 2020 | Bruker Corp (BRKR) | Chairman, President and Chief Executive Officer | $689,049 | $4,081,963 |
| 2019 | Bruker Corp (BRKR) | Chairman, President and Chief Executive Officer | $752,595 | $4,909,641 |
| 2018 | Bruker Corp (BRKR) | Chairman, President and Chief Executive Officer | $730,675 | $4,479,899 |
| 2017 | Bruker Corp (BRKR) | Chairman, President and Chief Executive Officer | $704,269 | $4,872,009 |